spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

BioGenes Celebrates 25 Years of Excellence in Quality Control of Biotherapeutics

BioGenes

BioGenes GmbH, specializing in ELISA development and production, is celebrating its 25-year anniversary

Berlin, Germany, July 25, 2017 / B3C newswire/ -- BioGenes GmbH, specializing in ELISA development and production, is celebrating its 25-year anniversary. In 1992 the scientists Dr. Alexander Knoll and Dr. Sergej Ovodov set out with a vision to provide services and kits for the quality control of biotherapeutics. Over the course of the last 25 years, BioGenes’s vision has become a reality. BioGenes has grown from a small niche start-up firm providing antibody services to a worldwide leading provider of host cell protein (HCP) assays, customized ELISA development and analytical services.

Company founder and CEO Dr. Alexander Knoll remarked: "This is an incredible milestone for our company. The company has achieved this success through the hard work, passion, and dedication of our team members and our culture of customer service that exists throughout the entire organization. I’m proud to say that our teams consistently exceed client expectations by providing the most efficient, and proactive services to each and every project.”

"To this day BioGenes is still driven by the entrepreneurial spirit of our founders, which has enabled us to constantly expand our offering portfolio," said Dagmar Schwertner, Marketing & Sales Director, who has been with the company for 23 years. "In the fall, BioGenes will be launching a new product for immunogenicity testing.” As of today, BioGenes’ offerings include:

1. Customized ELISA Development
2. Multi-product (platform) and specific HCP assays
3. Generic HCP ELISAs (360-HCP assays for CHO cells and E.coli)
4. Customized Antibodies (incl. anti-idiotypic antibodies)
5. Analytical Services (2D DIGE, 2D Western Blot, HCP coverage determination etc.)

In its 25 years, BioGenes has delivered thousands of projects to our customers. Find out more about BioGenes at www.BioGenes.de
phone +49 (0)30 6576 2396
web www.biogenes.de/
email Köpenicker Straße 325, D-12555 Berlin, Germany
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Synpromics expands facilities to meet demand for revolutionary gene control technology

Edinburgh, UK, 11th September 2017 - Synpromics Ltd, the leader in gene control and synthetic promoter development, today moves to new world-class facilities at the Roslin Innovation Centre. Synpromics is expanding to meet increasing global demand for its cutting-edge gene control technology, and is the first company to move into the new custom-built centre based at the University of Edinburgh’s Easter Bush Campus.
More info >>


White Papers

Case Study: Precision Pen Injector™

SHL Group

The Precision Pen Injector (PPI™) is an injector originally designed to deliver small yet highly precise doses of Restylane® Skinbooster™, a treatment produced by Swedish biomedical firm Q-Med AB (now Galderma) for revitalizing the skin. This innovative device received praises from doctors and clinicians alike for its ease-of-use and compact design at the 2009 IMCAS (International Master Course on Aging Skin), where the product was first officially launched. Furthermore, the PPI™ was recognized with the prestigious red dot design award for product design.
More info >>

Industry Events

Clinical Trial Supply New England 2018

7-8 March 2018, Boston, MA, USA

Clinical Trial Supply New England has now reached its 7th birthday! For the 7th annual Clinical Trial Supply New England 2018 conference, we have speakers who will focus primarily on discussing case studies, drawing from their own experiences to share the highs and lows for you to adopt in your trials.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement